Scholarlink

<p>Gastric cancer (GC) remains a significant global health challenge, and the relationship between the gut microbiota and GC has garnered increasing attention. A growing body of research has demonstrated that the gut microbiota plays a key role in the development and progression of GC through a complex network of mechanisms. This review analyzes key factors such as microbial dysbiosis, urease-assisted colonization, and the formation of nitrosamines and other carcinogenic metabolites, highlighting their influence on GC. Additionally, we emphasize the roles of chronic inflammation and immune dysregulation, which are driven by microbial activities, in gastric carcinogenesis. The recent advances in microbiota-based biomarkers for GC are summarized. The clinical value of microbial-related therapies, including probiotics, antibiotic therapy, and fecal microbiota transplantation is also explored. This review discusses the complex and close relationship between the gut microbiota and GC, along with its clinical implications. It aims to provide deeper insights into dysbiosis-related GC research, the development of microbiota-based diagnostic biomarkers, and the advancement of treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of gut microbiota in the development, diagnosis, and treatment of gastric cancer

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Manlin Hu,
  • Yuyang Xiao,
  • Xupeng Zhang,
  • Jialin Guo,
  • Tianhong Shen,
  • Yuzhe Wang,
  • Jiaqi Deng,
  • Dan Liu

摘要

Gastric cancer (GC) remains a significant global health challenge, and the relationship between the gut microbiota and GC has garnered increasing attention. A growing body of research has demonstrated that the gut microbiota plays a key role in the development and progression of GC through a complex network of mechanisms. This review analyzes key factors such as microbial dysbiosis, urease-assisted colonization, and the formation of nitrosamines and other carcinogenic metabolites, highlighting their influence on GC. Additionally, we emphasize the roles of chronic inflammation and immune dysregulation, which are driven by microbial activities, in gastric carcinogenesis. The recent advances in microbiota-based biomarkers for GC are summarized. The clinical value of microbial-related therapies, including probiotics, antibiotic therapy, and fecal microbiota transplantation is also explored. This review discusses the complex and close relationship between the gut microbiota and GC, along with its clinical implications. It aims to provide deeper insights into dysbiosis-related GC research, the development of microbiota-based diagnostic biomarkers, and the advancement of treatment strategies.